Founded in 2012, Caliway focuses on breakthrough medical aesthetics and inflammatory medicine discovery of small-molecule therapeutics, targeting areas with unmet medical needs and a growing market worth more than $10 billion to expand their market opportunity. Our leading candidate, CBL-514, is a first-in-class new drug that can trigger adipocyte apoptosis at the injection site and reduce subcutaneous fat effectively without ...
Founded in 2012, Caliway focuses on breakthrough medical aesthetics and inflammatory medicine discovery of small-molecule therapeutics, targeting areas with unmet medical needs and a growing market worth more than $10 billion to expand their market opportunity. Our leading candidate, CBL-514, is a first-in-class new drug that can trigger adipocyte apoptosis at the injection site and reduce subcutaneous fat effectively without causing tissue necrosis or prominent side effects. The results of the CBL-514 clinical trial demonstrated its promising potential in competing in the fat reduction market that is worth more than USD$100 billion.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.